Higher grade gliomas showed more blood vessel growth signals
Original title: Angiogenic Factors in Adult Diffuse Glioma and Their Correlation With Tumor Grade: An Observational Study.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This only looked at tumor samples from people. No treatment was tested.
The short version
In tumor samples from 50 adults, the more aggressive tumors had more of a protein that helps tumors grow new blood vessels.
What was studied. Researchers looked at tumor tissue from 50 adults with diffuse glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary. They stained the tissue to measure a protein called VEGF and to count the tiny blood vessels inside the tumor.
What they found. VEGF was found in 44 of the total 50 cases. The tumors with the most VEGF tended to be the higher grade tumors. Most samples also had a lot of tiny blood vessels, with counts that ranged from 15 to 105.
What this means, and what it doesn't
What it could mean: Tumors grow their own blood supply, and this study adds to the picture of how that works in glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary. Drugs that block VEGF already exist. Work like this helps researchers think about who those drugs might help. It does not change what treatment you get today.
What it doesn't mean: This is not a new treatment. Nobody was given a drug in this study. Researchers only looked at tumor tissue under a microscope after surgery. It does not show that blocking VEGF makes people live longer. It is a small study of 50 people at one point in time. It is not a cure, and it is a long way from changing everyday care.
Source: PubMed, June 13, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.